Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

RARE PHOTOS: Longeveron | Rare Historical Photos

A $30 Million Reason to Buy Penny Stock Longeveron Today

Longeveron shares rip higher as the biotech firm raises $30 million via a private placement. Here’s why it may not be too late to invest in LGVN stock yet.

EXCLUSIVE: Longeveron's Lomecel-B Product Gets US FDA Fast Track Designation For Treatment Of Hypoplastic Left Heart Syndrome in Infants

EXCLUSIVE: Longeveron's Lomecel-B Product Gets US FDA Fast Track Designation For Treatment Of Hypoplastic Left Heart Syndrome in Infants

The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to Longeveron Inc (NASDAQ: LGVN) Lomecel-B for the treatment of Hypoplastic Left Heart Syndrome (HLHS).

LGVN: Alzheimer's Study Gains Traction as CEO Search Continues

By Brad Sorensen, CFA NASDAQ:LGVN READ THE FULL LGVN RESEARCH REPORT

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

LGVN: CEO Leaving but Progress Continues

By Brad Sorensen, CFA NASDAQ:LGVN READ THE FULL LGVN RESEARCH REPORT

Recap: Longeveron Q1 Earnings

Longeveron (NASDAQ:LGVN) reported its Q1 earnings results on Friday, May 13, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Longeveron's Earnings: A Preview

Longeveron (NASDAQ:LGVN) is set to give its latest quarterly earnings report on Friday, 2022-05-13. Here's what investors need to know before the announcement. Analysts estimate that Longeveron will report an earnings per share (EPS) of $-0.22.

The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves

Here's a roundup of top developments in the biotech space over the last 24 hours:

inkl

Read news from The Economist, FT, and more,
with one subscription

EXCLUSIVE: Longeveron Adds Miami Veterans Affairs Site To Its Ongoing Mid-Stage Alzheimer's Trial

EXCLUSIVE: Longeveron Adds Miami Veterans Affairs Site To Its Ongoing Mid-Stage Alzheimer's Trial

Longeveron Inc (NASDAQ: LGVN) has announced a Cooperative Research and Development Agreement (CRADA) with the United States Department of Veterans Affairs (VA) to add Miami VA clinical site to its ongoing Phase 2 Alzheimer’s Disease (AD) trial.

5 Short Squeeze Candidates To Watch: Aterian Tops The List, System1 Group And Longeveron Join Leaderboard

5 Short Squeeze Candidates To Watch: Aterian Tops The List, System1 Group And Longeveron Join Leaderboard

Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move.

12 Health Care Stocks Moving In Tuesday's Intraday Session

12 Health Care Stocks Moving In Tuesday's Intraday Session

LGVN: LGVN Publishes Positive Alzheimer's Results

By Brad Sorensen, CFA NASDAQ:LGVN READ THE FULL LGVN RESEARCH REPORT

Why Longeveron Shares Are Surging Today

Why Longeveron Shares Are Surging Today

Longeveron Inc (NASDAQ: LGVN) shares are trading higher Thursday after the company announced the publication of results from a Phase 1 trial testing Lomecel-B on patients with mild Alzheimer's disease in "Alzheimer's & Dementia: The Journal of the Alzheimer's Association."

Benzinga's Top Ratings Upgrades, Downgrades For March 24, 2022

Benzinga's Top Ratings Upgrades, Downgrades For March 24, 2022

LGVN: Longeveron Continues to Make Progress

By Brad Sorensen, CFA NASDAQ:LGVN READ THE FULL LGVN RESEARCH REPORT

Get all your
news in one place.

100's of premium titles.
One news app.

LGVN: Using Cellular Technology to Ease Major Medical Issues

By Brad Sorensen, CFA NASDAQ:LGVN READ THE FULL LGVN RESEARCH REPORT

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

B of A Securities

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Alzheimer Disease

Places

363,638 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play